DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Mazdutide is a GLP-1/glucagon dual agonist, China-approved in 2026, with US filing dependent on Lilly partnership. ~15% weight loss in Phase 3 China trials.
Like survodutide, mazdutide pairs GLP-1 agonism with glucagon-receptor activity. The glucagon arm increases energy expenditure and supports liver-fat reduction. Originally licensed from Eli Lilly to Innovent for China development.
Versus tirzepatide: mazdutide’s ~15% trails Zepbound’s ~21%, but it adds glucagon-driven metabolic effects and may have a fatty-liver advantage. Most relevant to the US market only if Lilly pursues US registration.
China approval 2026 (first market). US pathway uncertain; depends on Lilly or partner pursuing FDA registration, likely 2027 or later.
Primarily a signal of where dual-agonist development is heading. US patients have no near-term access route.
Editorial summary of investigational drugs not yet FDA-approved. Trial data and timelines change. Not medical advice; do not delay current treatment waiting for pipeline agents.